---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-023480"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2026-07-14T13:23:23+00:00"
generated_at: "2026-07-14T13:24:06.169630+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Genprex files 1:22 reverse stock split to address Nasdaq bid price deficiency; faces delisting risk

## Summary
- Reverse stock split at 1:22 ratio effective July 16, 2026; shares outstanding to reduce from ~11.1M to ~505K.
- Received Nasdaq delisting notice on June 10, 2026 for failing to maintain $1.00 bid price; requested hearing.
- Acclaim-1 Phase 2a enrolling; Acclaim-3 Phase 2 expansion enrolling, interim analysis expected H1 2027.
- Identified TROP-2 and PTEN as predictive biomarkers for REQORSA; plan to evaluate high TROP-2 expression.
- No guarantee reverse split will regain compliance; risk of delisting and adverse impact on stock price and capital access.

## SEC filing metadata
- accession: 0001437749-26-023480
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2026-07-14T13:23:23+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.03, 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774926023480/0001437749-26-023480-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774926023480/gnpx20260630_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-023480
- JSON: https://secwatch.observer/filing/0001437749-26-023480.json
- Plain text: https://secwatch.observer/filing/0001437749-26-023480.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.